Avicanna Backs University of Calgary Trial to Map Optimal Oral THC Dosing

Avicanna ( (TSE:AVCN) ) has shared an update.

Avicanna has partnered with researchers at the University of Calgary’s Cumming School of Medicine to launch a Phase I randomized, double-blind, placebo-controlled dose-finding clinical trial on its proprietary oral THC capsules for anxiety and stress. The trial will test single doses of 6 mg, 9 mg, and 15 mg THC versus placebo in 24 healthy adults, assessing psychometric measures of anxiety, mood, intoxication, cardiovascular effects, stress biomarkers, and pharmacokinetics to better define the therapeutic window and individual variability in oral THC response.

The study uses Avicanna’s AVCN319301b capsules built on its Solid Self-Emulsifying Drug Delivery System technology, designed to improve absorption and reduce variability common with lipophilic cannabinoids. By supporting this investigator-led trial, which complements an existing osteoarthritis study using the same capsules, Avicanna is deepening its clinical collaborations, bolstering the evidence base for its delivery platform, and advancing its pharmaceutical pipeline in cannabinoid-based therapeutics.

The most recent analyst rating on (TSE:AVCN) stock is a Hold with a C$0.19 price target. To see the full list of analyst forecasts on Avicanna stock, see the TSE:AVCN Stock Forecast page.

Spark’s Take on AVCN Stock

According to Spark, TipRanks’ AI Analyst, AVCN is a Neutral.

The score is held back primarily by continued losses and negative cash flow despite strong revenue growth and improving gross margins, plus a weak technical trend (price below major moving averages and negative MACD). Valuation also screens poorly due to the negative P/E, consistent with the lack of current profitability.

To see Spark’s full report on AVCN stock, click here.

More about Avicanna

Avicanna Inc. is a commercial-stage international biopharmaceutical company specializing in the development, manufacturing, and commercialization of plant-derived cannabinoid-based products for global medical and pharmaceutical markets. Its portfolio spans more than thirty proprietary, evidence-based formulations across oral, sublingual, topical, and transdermal formats, anchored by brands such as RHO Phyto in Canada and supported by a dedicated medical cannabis care platform, MyMedi.ca.

YTD Price Performance: -22.22%

Average Trading Volume: 57,182

Technical Sentiment Signal: Sell

Current Market Cap: C$21.99M

For a thorough assessment of AVCN stock, go to TipRanks’ Stock Analysis page.